Laboratory of Basic Science on Healthy Longevity, Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo, Japan.
Research Center for Food Safety, Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo, Japan.
Int Arch Allergy Immunol. 2020;181(6):446-455. doi: 10.1159/000506945. Epub 2020 Apr 16.
Wheat is known as the most widely consumed food all over the world. Although many types of wheat allergy have been recognized, their treatment still has a long way to go due to the complex pathogenesis. Oral immunotherapy (OIT) is under investigation for the treatment of wheat allergies. Previous studies have demonstrated that OIT using intact wheat allergens can induce tolerance, but is accompanied by a high risk of anaphylactic reactions.
Our objective was to prepare modified wheat allergens with hypoallergenic and tolerance-inducing properties to reduce adverse effects during immunotherapy.
Wheat gliadin was degraded by hydrolysis with pepsin and trypsin, and then the hydrolysate was deamidated with hydrochloric acid. The IgE-binding capacity and T cell reactivity of the degraded gliadins were evaluated in vitro. Pepsin-digested gliadin (peptic-GLI) was applied in a mouse model to investigate whether it would induce oral tolerance.
Degradation with pepsin decreased IgE-binding capacity and maintained T cell reactivity. Oral administration of peptic-GLI to mice before sensitization and challenge with gliadin could significantly suppress the production of IgE, IgG1, and type 2 T helper cytokines. Moreover, the development of anaphylactic reactions and allergic responses of the small intestine induced by gliadin challenge were inhibited by oral administration of peptic-GLI.
The findings of this study indicate that peptic-GLI with low allergenicity and potential for tolerance induction may become useful in wheat immunotherapy with less adverse effects.
小麦被称为全世界最广泛食用的食物。尽管已经认识到许多种小麦过敏,但由于发病机制复杂,其治疗仍有很长的路要走。口服免疫疗法(OIT)正在被研究用于治疗小麦过敏。以前的研究表明,使用完整的小麦过敏原的 OIT 可以诱导耐受,但伴随着过敏反应的高风险。
我们的目的是制备具有低致敏性和诱导耐受特性的改良小麦过敏原,以减少免疫治疗过程中的不良反应。
用胃蛋白酶和胰蛋白酶水解麦醇溶蛋白,然后用盐酸使水解产物脱酰胺。体外评估了降解麦醇溶蛋白的 IgE 结合能力和 T 细胞反应性。在小鼠模型中应用胃蛋白酶消化的麦醇溶蛋白(胃蛋白酶-GLI),以研究其是否会诱导口服耐受。
胃蛋白酶降解降低了 IgE 结合能力并保持了 T 细胞反应性。在致敏前和麦醇溶蛋白激发前给予小鼠口服胃蛋白酶-GLI,可以显著抑制 IgE、IgG1 和 2 型 T 辅助细胞因子的产生。此外,口服胃蛋白酶-GLI 抑制了由麦醇溶蛋白激发引起的过敏反应和小肠过敏反应的发展。
这项研究的结果表明,具有低致敏性和潜在诱导耐受能力的胃蛋白酶-GLI 可能成为小麦免疫治疗中较少不良反应的有用方法。